Wanbury Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Wanbury Limited reported unaudited Q1 FY26 (quarter ended June 30, 2025) results with revenue from operations of ₹163.18 crore, up roughly 24% from ₹131.11 crore in the same quarter last year. Profit after tax surged to ₹13.49 crore from just ₹1.04 crore a year ago — a more than 12-fold jump — helped by lower tax outflow and better operating margins. Basic EPS came in at ₹4.12 versus ₹0.32 in Q1 FY25. Apart from results, the board approved 91,500 stock options to employees under the ESOP 2016 scheme, re-appointed Whole-time Director Mr. Chandran Krishnamoorthy for another 5 years, and initiated the closure of three non-operational foreign subsidiaries in the Netherlands, China, and the UAE. The statutory auditor, Kapoor & Parekh Associates, issued an unmodified (clean) review report on both the standalone and consolidated numbers.
Strong YoY revenue growth, a sharp rebound in profitability, and visible margin expansion are positive signals for shareholders. The low base of Q1 FY25 flatters the headline PAT growth, but finance costs remain elevated at ₹7.54 crore and warrant monitoring. The subsidiary closures are housekeeping with no impact on revenue, while the ESOP grant and director re-appointment are routine governance items.